The board of Swedish Orphan Biovitrum AB (Sobi) has said the withdrawal of a takeover bid by a private equity consortium won’t change the company’s strategic objective of becoming a global leader in rare diseases. The statement, issued on 3 December, follows an announcement by the consortium that it was cancelling its $8.1 billion tender offer for the Swedish company after only 87.3% of shareholders accepted it. The consortium was looking to buy more than 90% of Sobi’s outstanding shares.
